Zhengye Biotechnology Holding (ZYBT) Common Equity (2022 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Common Equity for 4 consecutive years, with $43.2 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Common Equity fell 11.89% year-over-year to $43.2 million in Q4 2025; TTM through Dec 2025 was $43.2 million, a 11.89% decrease from a year earlier, with the FY2025 full-year figure at $43.9 million, down 9.21% from the prior year.
• Common Equity was $43.2 million for Q4 2025 at Zhengye Biotechnology Holding, down from $51.0 million in the prior quarter.
• Over five years, Common Equity peaked at $51.0 million in Q2 2025 and troughed at $43.2 million in Q4 2025.
• A 4-year average of $48.1 million and a median of $49.1 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity grew 4.16% in 2024 and dropped 11.89% in 2025, its largest moves.
• Over 4 years, Common Equity stood at $50.2 million in 2022, then fell by 6.09% to $47.1 million in 2023, then gained by 4.16% to $49.1 million in 2024, then retreated by 11.89% to $43.2 million in 2025.
• The last three Common Equity figures came in at $43.2 million (Q4 2025), $51.0 million (Q2 2025), and $49.1 million (Q4 2024), per Business Quant data.